Neuren Pharmaceuticals Says Angelman Syndrome Drug Shows Promise in Trial; Shares Down 6%
Neuren Pharmaceuticals Says Angelman Syndrome Drug Shows Promise in Trial; Shares Down 6%
Neuren制药表示，安吉尔曼综合症药物在试验中显示出有希望的成果；股价下跌6%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间